A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo
Articolo
Data di Pubblicazione:
2017
Citazione:
A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo / A. Dal Corso, R. Gebleux, P. Murer, A. Soltermann, D. Neri. - In: JOURNAL OF CONTROLLED RELEASE. - ISSN 0168-3659. - 264(2017 Oct 28), pp. 211-218. [10.1016/j.jconrel.2017.08.040]
Abstract:
Antibody-drug conjugates are generally believed to crucially rely on internalization into cancer cells for therapeutic activity. Here, we show that a non-internalizing antibody-drug conjugate, based on the F16 antibody specific to the alternatively spliced A1 domain of tenascin-C, mediates a potent therapeutic activity when equipped with the anthracycline PNU159682. The peptide linker, connecting the F16 antibody in IgG format at a specific cysteine residue to the drug, was stable in serum but could be efficiently cleaved in the subendothelial extracellular matrix by proteases released by the dying tumor cells. The results indicate that there may be a broader potential applicability of non-internalizing antibody-drug conjugates for cancer therapy than what had previously been assumed.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Anthracyclines; Antibodies; Antibody-drug conjugates; Protein engineering; Vascular targeting; Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Female; Humans; Immunoconjugates; Immunoglobulin G; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Tenascin; Tumor Burden
Elenco autori:
A. Dal Corso, R. Gebleux, P. Murer, A. Soltermann, D. Neri
Link alla scheda completa:
Link al Full Text: